264 related articles for article (PubMed ID: 19398079)
1. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).
Ghali JK; Wikstrand J; Van Veldhuisen DJ; Fagerberg B; Goldstein S; Hjalmarson A; Johansson P; Kjekshus J; Ohlsson L; Samuelsson O; Waagstein F; Wedel H;
J Card Fail; 2009 May; 15(4):310-8. PubMed ID: 19398079
[TBL] [Abstract][Full Text] [Related]
2. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Hjalmarson A; Goldstein S; Fagerberg B; Wedel H; Waagstein F; Kjekshus J; Wikstrand J; El Allaf D; Vítovec J; Aldershvile J; Halinen M; Dietz R; Neuhaus KL; Jánosi A; Thorgeirsson G; Dunselman PH; Gullestad L; Kuch J; Herlitz J; Rickenbacher P; Ball S; Gottlieb S; Deedwania P
JAMA; 2000 Mar; 283(10):1295-302. PubMed ID: 10714728
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
[TBL] [Abstract][Full Text] [Related]
4. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
Wikstrand J; Wedel H; Castagno D; McMurray JJ
J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
6. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
Gullestad L; Wikstrand J; Deedwania P; Hjalmarson A; Egstrup K; Elkayam U; Gottlieb S; Rashkow A; Wedel H; Bermann G; Kjekshus J;
J Am Coll Cardiol; 2005 Jan; 45(2):252-9. PubMed ID: 15653024
[TBL] [Abstract][Full Text] [Related]
7. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Ghali JK; Piña IL; Gottlieb SS; Deedwania PC; Wikstrand JC;
Circulation; 2002 Apr; 105(13):1585-91. PubMed ID: 11927527
[TBL] [Abstract][Full Text] [Related]
8. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
Jánosi A; Ghali JK; Herlitz J; Czuriga I; Klibaner M; Wikstrand J; Hjalmarson A;
Am Heart J; 2003 Oct; 146(4):721-8. PubMed ID: 14564329
[TBL] [Abstract][Full Text] [Related]
9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
Lancet; 1999 Jun; 353(9169):2001-7. PubMed ID: 10376614
[TBL] [Abstract][Full Text] [Related]
10. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
11. How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Wikstrand J; Wedel H; Ghali J; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F
Card Electrophysiol Rev; 2003 Sep; 7(3):264-75. PubMed ID: 14739726
[TBL] [Abstract][Full Text] [Related]
12. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study.
Goldstein S; Fagerberg B; Hjalmarson A ; Kjekshus J; Waagstein F; Wedel H; Wikstrand J;
J Am Coll Cardiol; 2001 Oct; 38(4):932-8. PubMed ID: 11583861
[TBL] [Abstract][Full Text] [Related]
13. Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension.
Herlitz J; Wikstrand J; Denny M; Fenster P; Heywood T; Masszi G; Rasmussen S; Thorgeirsson G; Wachtell K;
J Card Fail; 2002 Feb; 8(1):8-14. PubMed ID: 11862577
[TBL] [Abstract][Full Text] [Related]
14. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Wikstrand J; Hjalmarson A; Waagstein F; Fagerberg B; Goldstein S; Kjekshus J; Wedel H;
J Am Coll Cardiol; 2002 Aug; 40(3):491-8. PubMed ID: 12142116
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure.
Deedwania PC; Gottlieb S; Ghali JK; Waagstein F; Wikstrand JC;
Eur Heart J; 2004 Aug; 25(15):1300-9. PubMed ID: 15288157
[TBL] [Abstract][Full Text] [Related]
16. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
[TBL] [Abstract][Full Text] [Related]
17. MERIT-HF mortality and morbidity data.
Hjalmarson A; Fagerberg B
Basic Res Cardiol; 2000; 95 Suppl 1():I98-103. PubMed ID: 11192362
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
19. Metoprolol: a review of its use in chronic heart failure.
Prakash A; Markham A
Drugs; 2000 Sep; 60(3):647-78. PubMed ID: 11030472
[TBL] [Abstract][Full Text] [Related]
20. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure.
Groenning BA; Nilsson JC; Sondergaard L; Fritz-Hansen T; Larsson HB; Hildebrandt PR
J Am Coll Cardiol; 2000 Dec; 36(7):2072-80. PubMed ID: 11127443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
